^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Ovarian Cancer

    Related cancers:
    14h
    FLORA-4: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (clinicaltrials.gov)
    P3, N=615, Active, not recruiting, CanariaBio Inc. | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial primary completion date
    |
    carboplatin • paclitaxel • OvaRex (oregovomab)
    15h
    INX-315-01: Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer (clinicaltrials.gov)
    P1/2, N=150, Recruiting, Incyclix Bio | Trial completion date: Jun 2026 --> Sep 2027 | Trial primary completion date: Dec 2025 --> Jul 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Verzenio (abemaciclib) • fulvestrant • INX-315
    16h
    Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers (clinicaltrials.gov)
    P1, N=52, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Aug 2030 --> Dec 2026
    Trial completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • KEAP1 (Kelch Like ECH Associated Protein 1) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
    |
    KRAS mutation • KRAS G12C • KEAP1 mutation • KRAS G12
    |
    Lynparza (olaparib) • Krazati (adagrasib)
    17h
    QPT-ORE-006: Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer (clinicaltrials.gov)
    P2, N=88, Active, not recruiting, CanariaBio Inc. | Trial primary completion date: Jan 2026 --> Oct 2026
    Trial primary completion date
    |
    carboplatin • paclitaxel • OvaRex (oregovomab)
    17h
    BWHS RoR: Scalable Communication Modalities for Returning Genetic Research Results (clinicaltrials.gov)
    P=N/A, N=926, Completed, Boston University | Active, not recruiting --> Completed
    Trial completion
    19h
    TREVI-OC-01: AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (clinicaltrials.gov)
    P3, N=289, Recruiting, AstraZeneca | N=46 --> 289
    Enrollment change • Platinum resistant
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan • torvutatug samrotecan (AZD5335)
    21h
    Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy (clinicaltrials.gov)
    P2, N=87, Not yet recruiting, National Cancer Institute (NCI)
    New P2 trial • Platinum sensitive
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)
    |
    BRCA2 mutation • BRCA1 mutation • HRD
    |
    Avastin (bevacizumab) • carboplatin • gemcitabine • pegylated liposomal doxorubicin • Trodelvy (sacituzumab govitecan-hziy) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
    1d
    Dihydroartemisinin Induces Ferroptosis in Ovarian Cancer via STAT3/GPX4 Signaling Pathway. (PubMed, Chin J Integr Med)
    Treatment with DHA can inhibit OC cell proliferation and induce ferroptosis in OC, and these effects may be predominantly mediated via STAT3/GPX4 signaling pathway.
    Journal
    |
    GPX4 (Glutathione Peroxidase 4) • SLC7A11 (Solute Carrier Family 7 Member 11)
    1d
    Impact of cancer outcome data source on the diagnostic accuracy of ovarian cancer prediction models: a primary care cohort study. (PubMed, BMJ Public Health)
    Using an OC exemplar, we found moderate variation in model performance and threshold accuracy when different data sources were used to define cancer. To ensure cancer prediction models perform as expected in real world clinical practice, gold standard data sources, such as CR data, should be used for model development and validation.
    Journal
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    1d
    A Nine-Year Diagnostic Odyssey of Refractory Psychiatric Symptoms Resolving After Resection of a CA19-9-Producing Ovarian Teratoma: A Case Report and Literature Review. (PubMed, Brain Behav)
    Ovarian teratomas may be associated with suspected cases of isolated autoimmune psychosis, even in the absence of typical neurological signs or positive autoantibodies. In such instances, CA19-9 elevation could serve as a nonspecific clue. Comprehensive imaging remains crucial for patients with atypical, treatment-resistant psychosis to avoid diagnostic delays.
    Review • Journal
    |
    CA 19-9 (Cancer antigen 19-9)
    1d
    Methods for Defining the Role of ADAMTS1 in the Ovary. (PubMed, Methods Mol Biol)
    These findings highlight the precise action of this enzyme in maintaining normal ovarian functions. This chapter describes the methods for detecting, localizing, and determining the activity of ADAMTS1 in the ovary.
    Journal
    |
    ADAMTS1 (ADAM Metallopeptidase With Thrombospondin Type 1 Motif 1)
    1d
    Targeting circSFPQ_008/SFPQ/BRCA1 axis for overcoming platinum resistance in ovarian cancer. (PubMed, MedScience)
    Exploration of the upstream mechanism revealed that hsa_circSFPQ_008, which was derived from the SFPQ parental gene, recruits HDAC1 to modify H3K27Ac of the SFPQ promoter and regulates its expression. This study reveals a novel regulatory mechanism by which SFPQ is involved in platinum resistance of ovarian cancer, providing a new theoretical basis for the individualized and precise treatment of ovarian cancer.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HDAC1 (Histone Deacetylase 1)